Documente Academic
Documente Profesional
Documente Cultură
(WHO – GMP & ISO 9001: 2008 certified company)
Corporate Presentation
C P i
November 2014
2
Scheme of presentation
Industry overview
About the company
Milestones
Corporrate Presentation
Infrastructure
Key strengths
2014
3
Global Pharmaceutical Industry ‐ Overview
Global Pharma
l b l h Market in 2011
k
IMS institute estimates that Global Pharmaceutical
Industry to be US$ 956 Bn in 2011 and is estimated
15%
to grow at CAGR of 3‐6% during 2012 – 16. U.S (US$ Rest of the world United
2% 34% States
322 B ) f ll
322 Bn) followed by EU 5 (US$159 Bn) are the major
d b EU 5 (US$159 B ) th j Canada
markets that contributes to about 50% of the global
20%
market. Pharmerging
The term “Pharmerging”
The term Pharmerging market was coined by IMS
market was coined by IMS 17%
Corporrate Presentation
12%
to signify the growing shift of growth momentum to EU 5
Japan
emerging markets that includes Brazil, Russia,India
Top 10 therapy areas projections ‐ 2016
and China (BRIC). These markets are expected to
Therapy Areas
Therapy Areas Market Size (US$ Bn)
Size (US$ Bn)
achieve a CAGR of 12‐15% against that of 1‐4% of
hi CAGR f 12 15% i t th t f 1 4% f
Oncologics 83 – 88
developed markets during 2012 ‐16.
Antidiabetics 48 – 53
China leads the pack as Tier 1 market, is estimated Asthma/COPD 44 – 48
to have a pharmaceutical spending of US$ 155 to
to have a pharmaceutical spending of US$ 155 to Autoimmune 33 – 36
US$ 165 Bn by 2016. Lipid Regulators 31 – 34
Brazil, Russia, India put together as Tier 2 markets Angiotensin II 22 – 25
follows China and is expected to become a 100 – 110 HIV Antivirals 22 – 25
market by 2016. Antipsychotics 22 – 25
Vaccines 19 – 22
Source: IMS institute report Immunostimulants 16 – 18
2014
4
Indian Pharmaceutical Industry ‐ Overview
Mkt share by value ‐
k h b l therapy areas
h
Indian Pharmaceutical market is estimated to be at (2014)
US$ 21 Bn in 2014 growing at annual growth rate of
rd th 13% Alimentary
13%. It ranks 3 in volume and 14 value terms of
10%
manufacturing of pharma
f t i f h products globally.
d t l b ll Cardiovascular
India produces about 20% ‐ 24% of the global
9%
generic drug production. The generic market is 59% Respiratory
expected to explode with about US$ 60 bn expired
expected to explode with about US$ 60 bn expired 6%
Corporrate Presentation
Other therapeutic 3% Central Nervous
in 2012. Along with the opportunity offered by areas
Oncology
patent expired in 2007, the newly available market
is estimated to be about US$ 73 Bn.
Relative cost of production(US cost base)
Relative cost of production(US cost base)
Indian industry’s export is estimated to double by
reaching about US$ 18.2 Bn by 2016 from value of
US$ 12 bn in 2014
US 100
Indian pharmaceutical market is estimated to grow
Indian pharmaceutical market is estimated to grow
at a CAGR of about 17% to reach US$ 35.9Bn by Europe 85
2016. The domestic market could be broadly
classified into API, CRAMS, Formulations and
India 40
Biosimiliars.
Indian Pharmaceutical Market ‐ Major Market Segments
• Country boast a world class manufacturing infrastructure with about 161
USFDA, 90 MHRA, and 1,000 WHO GMP approved plants.
API India
India is poised to replace Italy to become second largest supplier of APIs to global
is poised to replace Italy to become second largest supplier of APIs to global
pharma industry.
The addressable export market estimated to be about US$ 8.7 Bn
CRAMS
Corporrate Presentation
Indian CRAMS market was estimated to be US$ 3.8 Bn in 2010, accounting for just
6% of US$ 67 Bn global outsourcing market.
Contract Manufacturing Operations (CMO) has dominated the market with about
US$ 2.3 Bn in size.
Formulations
The prescription and OTC market constitute the domestic formulations market.
It is estimated to be about US$ 10 Bn and is expected to achieve double digit
gro th dri en b co ntr ’s strong economic and demographic f ndamentals
growth driven by country’s strong economic and demographic fundamentals
Biosimiliars
Indian Biosimiliars is estimated to be of US$ 338 Mn in 2010 and is estimated to
have reached US$ 580 Mn in 2012.
The market is expected to explode by 2015 when US$ 79 Bn worth of biologicals is
expected to go off patent.
Source: IBEF , CARE, ICRA reports MMC Healthcare has presence in these segments
2014
6
Company Overview
MMC Healthcare Ltd (MMC) was founded by four Sales by therapy areas
pharmaceutical professionals (alumni of Madurai Medical Dermatology Pediatrics
1.62%
College), in 1987 as a partnership firm and was converted in 1.63% 3.65% Others
to a closely held public limited company in 1997. 4.66%
Ortho
The company’s major focus is into domestic branded
4.85%
formulation market (US$ 10 Bn Market size in 2010) serving Surgery
the therapy areas viz., Gynecology, Orthopedics, Surgery
19.82
and General Medicine etc
and General Medicine etc.,
Corporrate Presentation
63.78
63 78
%
%
A wide product profile of about 50 branded formulations Gynecology
Physicians
promoted by dedicated field force of 205 Medical
representatives guided by about 58 Managers at various Revenue growth Rs. In Cr
levels The field force reaches out to about 32 000 doctors
levels. The field force reaches out to about 32,000 doctors. cove
Company’s export division caters to 14 countries and has
43
applied for registration of products in 17 new countries 42.00
42
Wellness division was launched in 2009 by launching Noni 41.23
41
based herbal drink AbleTo , later converted to Ethical
40
Marketing.
39 38.47
MMC is actively exploring herbal medicine market and 38
ggeriatric segment for expansion.
g p 37
The company is actively exploring options for strategic 36
alliances like Co marketing of brands to expand its national FY 12 FY 13 FY 14
2014
presence
7
Contract Manufacturing – Himachal Pradesh Unit
MMC undertakes contract manufacturing as a part of its Sales of MMC HP unit by clients
business model.
In 2005, the promoters expanded the business by setting up 22%
an exclusive unit in Himachal Pradesh held by an Special
Purpose Vehicle (SPV), MMC Healthcare (HP) Ltd., MMC
Healthcare Ltd
The unit clocked a revenue of about Rs.21 Cr in FY 14.
Company’s prestigious clientele includes
Cipla, Lupin, Medopharm, Pharmed, Medispan etc.,
Corporrate Presentation
Other
Other
MMC intends to become a full fledged Contract Research Clients 78%
and Manufacturing Services (CRAMS) player by foraying into
formulation R&D.
During 18th & 19th July, MMC participated in Pharmac South Revenue growth Rs. In Cr
2014 organized by IDMA TNPSB as Exhibitor. Through this
exhibition, MMC has genarated large number of new 43
42.00
customers & expecting to bag to orders. 42 41.23
Fiscical incentives for this plant is ending as on May 2015. 41
Th f
Therefore MMC has acquired another unit at Himachal
MMC h i d th it t Hi h l 40
Pradesh for the purpose of extending excise benefits. This 39 38.47
unit will be operated as a subsidiary of MMC . This move 38
will help MMC to boost a top line growth of approximately 37
18 – 20 crores
18 20 crores from 2015
from 2015‐16 16 onwards.
onwards. 36
FY 12 FY 13 FY 14
2014
8
Milestones
MMC celebrated its 25 years of successful presence in Indian pharmaceutical industry in
2012 and is marching ahead with growth plans to propel itself to next orbit of growth.
Obtained ISO
Obtained ISO Geographic
Geographic
WHO – GMP approval 9001:2000
Launch of
expansion drive
for the plant certification
Wellness division
Inauguration of an Inauguration of new
Corporrate Presentation
exclusive plant in
l i l i corporate office
t ffi
Himachal Pradesh for
Contract Manufacturing
Converted as public
li it d
limited company
Acquired new
Product unit Trimurti at
1997
expansion drive
expansion drive Himachal
Kick started Pradesh
Training centre exports
Reconstruction of for employees
p
Chennai plant inaugurated
Incorporated as a
partnership company
2014
9
Key Management Profile
Company is run by the founding team, who are equipped with about three
decades of experience in the various faculties of Pharmaceutical Industry
Supported by long standing, experienced employee base, the company is now set
for the next phase of growth and is aggressively expanding the management team.
Mr. M. Ravichandran, Director – Production
He holds a bachelor of pharmacy degree. He heads the company's production operations in two
Corporrate Presentation
plants with 30 Years experience in pharmaceutical field He is also an Executive committee member
plants with 30 Years experience in pharmaceutical field. He is also an Executive committee member
of Himachal Pradesh Drug Manufacturers Association and Executive committee member of
Confederation of Indian Pharmaceutical Industry.
Mr. R.S. Jayaraman, Director – Exports
He holds a bachelor of pharmacy degree. He has vast international business experience in
pharmaceutical field. His area of expertise includes indenting and Sourcing for pharmaceutical global
businesses.
Mr. M. Rajarathinam
j hi , Director –
i Marketing & Finance
k i & i
He holds a bachelor of pharmacy degree and he has a vast experience in the field of pharma sales
and marketing. He heads MMC's strong marketing force and is the man behind the company's
innovative and dynamic marketing strategies. He also heads the company's finance operations. He Is
Holding The Position Of Chairman Of Indian Drug Manufacturers Association, Tamilnadu
g g , State Board
and Executive Committee member of Pharmaceutical Manufacturers Association, Tamilnadu and a
Special invitee for IDMA, Mumbai. Under his leadership, on July 18th & 19th , IDMA TNPSB had very
sussefully conducted Pharmac South 2014 at Chennai, which was appreciated by industry & has
2014 expanded the reach for the company.
10
Succession Plan
Mr. Subash Vallab
Holds a Commerce and Management degree & undergoing
Diploma in Pharmaceutical strategy management. Immediately
Corporrate Presentation
after completion, joined Alembic pharma (all India Rank 25) as
f l i j i d Al bi h ( ll I di k2 )
Medical Representative in Trichy HQ in Cardiac Diabetic division
to practically understand pharmaceutical selling. Then he moved
p y p g
to Mumbai and worked in Sales administration in Mumbai based
Tidal laboratories. In April’14 he joined MMC as a Management
Trainee and presently been assigned to create / update SOP in all
department of MMC
2014
11
Product Profile
MMC produces and markets products in 10 therapeutic segments.
The major focus is on four segments namely Gynecology, Orthopedics, Surgery, and
General Medicine.
Therapeutic Segment Key Brands Product Segment
Hemocare group Nutritional Supplement ‐ Hematinics
Pileum group Alimentary System
System ‐ Hemorrhoids
Corporrate Presentation
Product Profile
Therapeutic Segment Key Brands Product Segment
Medicold Respiratory System
Ator4u Cardio Vascular System – Cholesterol Control
Hemocare, Combit, Pileum Hematinics, Hair growth, Hemorrhoids
2014
13
Product Profile
Therapeutic Segment Key Brands Product Segment
ABLEto Complementary
p y Therapy –
py Herbal health drink
Wellness
Corporrate Presentation
Ophthalmology
EbMont Asthma & COPD
EbMont‐L Asthma & COPD
EbMont‐AL Asthma & COPD
Asthma & COPD
Respiratory Deflawin Asthma & COPD
2014
14
Facilities
MMC owns a WHO GMP, ISO 9001 – 2000 manufacturing facility at SIDCO Industrial
Estate, in Thirumazhisai, Chennai.
Area: 18,073 Sq Ft
Production Capacity: Tablets
Production Capacity: bl 250 Lakhs Tablets
kh bl
Capsules 100 Lakhs Capsules
Liquids 1.25 Lakhs Litres
Corporrate Presentation
Domestic presence in branded formulations
MMC boasts a 205 strong medical representatives Domestic Presence
and about 58 line managers at various levels covers
about 32,600 doctors across the country, where it
operates.
Thi SBU
This SBU contributes to about 60 % of the company’s
t ib t t b t 60 % f th ’
sale.
The company has a strong presence in South India
with significant presence in Karnataka, Tamil Nadu,
and Kerala with a share of 50% of overall sales.
and Kerala with a share of 50% of overall sales.
Corporrate Presentation
Orissa, Chhattisgarh and Jharkhand in Eastern region
also contribute about 23 % of the overall sales.
Maharashtra has a share of 12% of the sales.
MMC has entered Uttar Pradesh and Madhya
MMC has entered Uttar Pradesh and Madhya
Pradesh recently & is planning to launch West Bengal
& North‐east in 2015 to expand its national
presence.
The company also plans to become a pan India
organization by year 17‐18.
i i b 17 18
Company’s distribution network consists of 12 C&A
agents and 520 stockists in the regions it operates
Company is focusing on Respiratory (Physicians) &
Gynec segment
2014
16
International Presence
The company has registered 94 products in 14 countries and has applied for new
product registrations of 136 products in 31 countries (Of which 17 countries are new
geographical expansions). The new registrations are expected happen by early 2015.
R
Revenue from exports have increased by 160% in FY 14 compared to that of FY 13.
f t h i d b 160% i FY 14 d t th t f FY 13
Ukraine
Tajikistan
Products
Registered : 1 Products
Corporrate Presentation
Under Registered : 3
Registration : 3 Under
Registration: 4
Algeria Jordan
Products Products
Registered : 1 Registered: 3 Phili i
Philippines
Francophone Under
Registration :5
Under
Registration: 42
Zambia Vietnam
Products Under
Registered : 3 Registration :6
Under D.R.Congo Maldives Sri Lanka
Registration: 13
Registration: 13
Products Products Products
Registered :2 Registered : 23 Registered : 18
Under Under Under
Registration : 0 Registration : 10 Registration : 7
2014
17
Awards and Clientele
MMC healthcare ltd is affiliate d to leading industry body
associations like IDMA, CII, FICCI, and Pharmexil etc.,
The company was recently awarded with “The Emerging
Company of the year” at Pharma excellence awards function in
February 2013
Corporrate Presentation
The Emerging Company of the
The prestigious
h clientele includes
l l l d Year – February 2013
2014
18
Key Strengths
Strong Management Team:
Founded and managed by industry veterans equipped with about 3 decades of
experience in various faculties of the pharmaceutical industry.
Promoters represent industry bodies as a recognition of their expertise in the industry
P i d b di ii f h i i i h i d
Succession plan initiated already.
Significant presence in South India
Markets above 50 branded formulations with dominant presence in 4 therapy
segments.
Some of the key brands commanding good annual sales
> 6 crores – Hemocare
3‐6 crores – Medineuron & AC group
2‐3 crores
23 – Pileum
Pil
1‐2 crores – EbMont, COMBit, Cervispon, Medicam & Cystop
Product innovation:
The company continues to differentiate itself through product innovations
2014
19
Key Strengths
Intellectual Property:
Trade Mark: All MMC products have registered Brand Names conforming to the
regulations of Trade Mark registration.
Patent registration: MMC has already submitted application for patency for the
products PILEUM (Application no. 2644/CHE/2007) and COMBit (Application no.
2966/CHE/2009) with all the requisite details and awaiting the sanction of patency.
For another product Cureperium
Corporrate Presentation
F th d tC i th
the application for patency is to be submitted in the
li ti f t i t b b itt d i th
near future.
Well laid out growth plans: Medium term outlook : Strategy 2014 – 15
Th
The company has laid out a blue print for both medium and long term growth and is
h l id t bl i t f b th di dl t th d i
in the process of executing the plans
MMC looks for opportunities for Co marketing and alliances to expand its national
foot print
foot print
2014
20
Contact Information
Contact
Mr. M. Rajarathinam
Director – Marketing & Finance
Corporrate Presentation
Mob. No: + 91 9841047472
Email: mmcmrr87@gmail.com
Phone: 044‐24868412 / 8413, 2486 6348 / 6358
Fax: 044 – 2486 6378
Email: mmchealthcare@ymail.com
Website: mmchealthcareindia.com
2014
Thank You
Thank You
2014 Corporate Presentation 21